Chinese Biotech Licensing Surge Poses Risks for U.S. Biotech Stocks
U.S. biotech firms now license nearly a third of their drug candidates from China, raising investor concerns over dependency and execution risks. U.S.-listed biotech companies allocated roughly a third of their 2025 licensing spending to drugs originating in China, accordi